GenCurix Applies Breast Cancer Prognostic Diagnosis Successively at Tertiary Hospitals

GenCurix, a company specializing in cancer molecular diagnostics, announced on the 2nd that breast cancer prognosis tests can be received at 49 general hospitals including Seoul Asan Medical Center, Seoul St. Mary's Hospital, and Hwasun Chonnam National University Hospital.

Following the introduction by Samsung Medical Center last year, Seoul Asan Medical Center and Seoul St. Mary's Hospital have also adopted the breast cancer prognosis test. The breast cancer prognosis test, 'Jinswell BCT,' is the first test developed specifically for Asians. It is the only test in Korea to have obtained manufacturing and product approval from the Ministry of Food and Drug Safety. It provides accurate test results for Asians and reduces the burden through actual expense insurance.

In June last year, GenCurix presented research results at the American Society of Clinical Oncology (ASCO) demonstrating the superiority of Jinswell BCT compared to the globally top-selling breast cancer prognosis product in the United States. In January, the monthly number of tests reached 100.

In January this year, the Ministry of Health and Welfare designated 47 tertiary general hospitals for the 5th term. Among these, 35 tertiary general hospitals have adopted Jinswell BCT. Considering medical institutions that are in the process of introduction after approval from NECA (National Evidence-based Healthcare Collaborating Agency), Jinswell BCT is supplied to four out of five tertiary hospitals.

A GenCurix official stated, "The excellence of Jinswell BCT, recognized by the top medical institutions in Korea, will serve as a good reference for expansion into major Asian countries."